BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 34535985)

  • 1. Genome-Wide Association Study of NAFLD Using Electronic Health Records.
    Fairfield CJ; Drake TM; Pius R; Bretherick AD; Campbell A; Clark DW; Fallowfield JA; Hayward C; Henderson NC; Joshi PK; Mills NL; Porteous DJ; Ramachandran P; Semple RK; Shaw CA; Sudlow CLM; Timmers PRHJ; Wilson JF; Wigmore SJ; Harrison EM; Spiliopoulou A
    Hepatol Commun; 2022 Feb; 6(2):297-308. PubMed ID: 34535985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease.
    Chen Y; Du X; Kuppa A; Feitosa MF; Bielak LF; O'Connell JR; Musani SK; Guo X; Kahali B; Chen VL; Smith AV; Ryan KA; Eirksdottir G; Allison MA; Bowden DW; Budoff MJ; Carr JJ; Chen YI; Taylor KD; Oliveri A; Correa A; Crudup BF; Kardia SLR; Mosley TH; Norris JM; Terry JG; Rotter JI; Wagenknecht LE; Halligan BD; Young KA; Hokanson JE; Washko GR; Gudnason V; Province MA; Peyser PA; Palmer ND; Speliotes EK
    Nat Genet; 2023 Oct; 55(10):1640-1650. PubMed ID: 37709864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Kim NY; Ko JS
    Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits.
    Kitamoto A; Kitamoto T; Nakamura T; Ogawa Y; Yoneda M; Hyogo H; Ochi H; Mizusawa S; Ueno T; Nakao K; Sekine A; Chayama K; Nakajima A; Hotta K
    Endocr J; 2014; 61(7):683-9. PubMed ID: 24785259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
    Anstee QM; Darlay R; Cockell S; Meroni M; Govaere O; Tiniakos D; Burt AD; Bedossa P; Palmer J; Liu YL; Aithal GP; Allison M; Yki-Järvinen H; Vacca M; Dufour JF; Invernizzi P; Prati D; Ekstedt M; Kechagias S; Francque S; Petta S; Bugianesi E; Clement K; Ratziu V; Schattenberg JM; Valenti L; Day CP; Cordell HJ; Daly AK;
    J Hepatol; 2020 Sep; 73(3):505-515. PubMed ID: 32298765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Genetic Risk Score With NAFLD in An Ethnically Diverse Cohort.
    Wang J; Conti DV; Bogumil D; Sheng X; Noureddin M; Wilkens LR; Le Marchand L; Rosen HR; Haiman CA; Setiawan VW
    Hepatol Commun; 2021 Oct; 5(10):1689-1703. PubMed ID: 34558842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
    Lin YC; Chang PF; Chang MH; Ni YH
    Am J Clin Nutr; 2014 Apr; 99(4):869-74. PubMed ID: 24477042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program.
    Serper M; Vujkovic M; Kaplan DE; Carr RM; Lee KM; Shao Q; Miller DR; Reaven PD; Phillips LS; O'Donnell CJ; Meigs JB; Wilson PWF; Vickers-Smith R; Kranzler HR; Justice AC; Gaziano JM; Muralidhar S; Pyarajan S; DuVall SL; Assimes TL; Lee JS; Tsao PS; Rader DJ; Damrauer SM; Lynch JA; Saleheen D; Voight BF; Chang KM;
    PLoS One; 2020; 15(8):e0237430. PubMed ID: 32841307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network.
    Namjou B; Lingren T; Huang Y; Parameswaran S; Cobb BL; Stanaway IB; Connolly JJ; Mentch FD; Benoit B; Niu X; Wei WQ; Carroll RJ; Pacheco JA; Harley ITW; Divanovic S; Carrell DS; Larson EB; Carey DJ; Verma S; Ritchie MD; Gharavi AG; Murphy S; Williams MS; Crosslin DR; Jarvik GP; Kullo IJ; Hakonarson H; Li R; ; Xanthakos SA; Harley JB
    BMC Med; 2019 Jul; 17(1):135. PubMed ID: 31311600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic backgrounds in nonalcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Itoh Y
    Clin J Gastroenterol; 2018 Apr; 11(2):97-102. PubMed ID: 29492830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population.
    Cavalcante LN; Porto J; Mazo D; Longatto-Filho A; Stefano JT; Lyra AC; Carrilho FJ; Reis RM; Alves VAF; Sanyal AJ; Oliveira CP
    Ann Hepatol; 2022; 27(6):100728. PubMed ID: 35710086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GWAS-Identified Common Variants With Nonalcoholic Fatty Liver Disease in Chinese Children.
    Shang XR; Song JY; Liu FH; Ma J; Wang HJ
    J Pediatr Gastroenterol Nutr; 2015 May; 60(5):669-74. PubMed ID: 25522307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.
    Longo M; Meroni M; Paolini E; Erconi V; Carli F; Fortunato F; Ronchi D; Piciotti R; Sabatini S; Macchi C; Alisi A; Miele L; Soardo G; Comi GP; Valenti L; Ruscica M; Fracanzani AL; Gastaldelli A; Dongiovanni P
    Cell Mol Gastroenterol Hepatol; 2022; 13(3):759-788. PubMed ID: 34823063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
    Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
    Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.
    Walker RW; Belbin GM; Sorokin EP; Van Vleck T; Wojcik GL; Moscati A; Gignoux CR; Cho J; Abul-Husn NS; Nadkarni G; Kenny EE; Loos RJF
    J Hepatol; 2020 Jun; 72(6):1070-1081. PubMed ID: 32145261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
    Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
    Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
    Speliotes EK; Yerges-Armstrong LM; Wu J; Hernaez R; Kim LJ; Palmer CD; Gudnason V; Eiriksdottir G; Garcia ME; Launer LJ; Nalls MA; Clark JM; Mitchell BD; Shuldiner AR; Butler JL; Tomas M; Hoffmann U; Hwang SJ; Massaro JM; O'Donnell CJ; Sahani DV; Salomaa V; Schadt EE; Schwartz SM; Siscovick DS; ; ; ; Voight BF; Carr JJ; Feitosa MF; Harris TB; Fox CS; Smith AV; Kao WH; Hirschhorn JN; Borecki IB;
    PLoS Genet; 2011 Mar; 7(3):e1001324. PubMed ID: 21423719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
    Lin YC; Chang PF; Chang MH; Ni YH
    Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.